ADVA wins two MEF 3.0 Proof of Concept Awards
10.3.2021 21:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has jointly won two awards at the MEF 3.0 Proof of Concept (PoC) Showcase. The honors recognize innovation and leadership with emerging services and technologies involving AI, SD-WAN, service automation and more. The Judge’s Choice Award for the best overall PoC was presented to a multi-vendor solution using ADVA’s Ensemble NFV suite to deliver personalized and automatically generated live video content over optimized network slices. Leveraging AI video technology and uCPE hosting SD-WAN, the demo showed how service providers can meet demand for unique immersive experiences of events such as live sports. ADVA also won the Market Game Changer Award, recognizing the largest potential impact on the service provider market. This was presented for its collaboration on a PoC using ADVA Ensemble software to enable multi-edge cloud services. This technology will be key to empowering enterprises to provide low-latency, high-throughput applications such as smart factories and industrial IoT.
“Our award-winning demo, Revolutionizing Live Events, illustrates how cable network operators can deliver exciting new services in an entirely original way. We’ve shown that it’s now possible to offer a unique, differentiated experience of live events that puts audiences at the heart of the action. Sports or music fans could soon be selecting their own viewing angles and receiving coverage that automatically zooms and tracks in real time. And for service providers, this points to a simple and cost-effective way of enabling high-volume, high-margin entertainment services,” said James Buchanan, GM, Edge Cloud, ADVA. “We’ve shown that utilizing uCPE and network slicing over enterprise networks can transform the way video content is produced and distributed. This cloud-based, virtualized approach opens the door to new levels of flexibility and automation for video services. What’s more, it highlights the potential of uCPE as a platform for innovation ready to unleash an array of new applications and business models.”
Featuring ADVA’s Ensemble suite of NFV software, the Revolutionizing Live Events PoC highlighted new opportunities for service providers to meet the growing expectations of sports and entertainment audiences. Driven by compute-based AI/ML, MEF-defined network slicing and lightweight uCPE running SD-WAN, the demo showed how network resources can be utilized to provide automated, highly personalized video content.
ADVA’s other award-winning PoC was the Orchestrated Multi-Edge Clouds demo. For this, the Ensemble NFV suite was deployed to manage and orchestrate SD-WAN, IoT, 5G networking and other edge-cloud technologies, seamlessly enabling the distribution of smart manufacturing resources between on-premises and network edge cloud environments. This demo paves the way for enterprises to purchase mission-critical applications and services flexibly and on demand.
“Our multi-edge cloud MEF 3.0 PoC is a key step in helping businesses to improve operational efficiency as they continue to digitize and automate their processes. It shows how service providers can accelerate adoption of multi-edge cloud services through the orchestration of applications and connectivity on open edge compute platforms. Winning the Market Game Changer Award underlines the impact on enterprises of being able to instantly purchase applications such as IoT, SD-WAN and wireless network access from a single managed service provider and have them automatically deployed across multiple cloud platforms,” commented Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Using our Ensemble NFV software, this PoC proves that it’s now possible to relieve businesses of the responsibility and burden of multi-vendor system integration. This creates a major opportunity for service providers. They can offer on-demand, managed edge services and connectivity on open edge compute platforms that can be deployed in multiple locations. And, using advanced analytics, they can select the best edge location for IoT applications to meet SLAs.”
More information about the Revolutionizing Live Events PoC is available here: https://adva.li/mef-poc-live-events.
Further details on the Orchestrated Multi-Edge Clouds demo can be viewed here: https://adva.li/mef-poc-multi-edge-clouds.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005482/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom